Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias

被引:152
作者
Benderra, Z [1 ]
Faussat, AM [1 ]
Sayada, L [1 ]
Perrot, JY [1 ]
Chaoui, D [1 ]
Marie, JP [1 ]
Legrand, O [1 ]
机构
[1] Univ Paris 06, Hop Hotel Dieu, Lab INSERM, Dept Clin Hematol, Paris, France
关键词
D O I
10.1158/1078-0432.CCR-04-0795
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Recently, a new ABC protein, breast cancer resistance protein (BCRP), was described. But its prognosis is not known in acute myeloid leukemia (AML). In addition, the prognosis of P-glycoprotein (Pgp) and BCRP in patients treated homogeneously by the same anthracycline (daunorubicin, idarubicin, or mitoxantrone) during all of the treatment with aracytine is not known. Therefore, we have evaluated the relationship between drug resistance phenotype, in vitro anthracene sensitivity, and the relation to treatment outcome. Experimental Design: We have analyzed 149 AML treated according to protocol of the European Organization for Research and Treatment of Cancer group. The prognostic value of BCRP and Pgp were analyzed in the whole population and according to intercalating agent. Results: BCRP was a prognostic factor, for achievement of complete remission (43% in positive patients and 69% in negative patients, P = 0.005), the 4-year disease-free survival (12% versus 33%, P = 0.03), and the 4-year overall survival (19% versus 38%, P = 0.003). When BCRP expression and Pgp function were categorized in three groups, +/+, +/- or -/+, and -/-, the achievement of complete remission was 45%, 66%, and 90% (P = 0.0003), the 4-year disease-free survival was 8%, 26%, and 40% (P = 0.01), and the 4-year overall survival was 16%, 37%, and 48% (P = 0.001), respectively. Pgp function was a prognostic factor in patients treated by daunorubicin and idarubicin but not by mitoxantrone. In contrast, BCRP expression was a prognostic factor in patients treated by daunorubicin and mitoxantrone but not by idarubicin. Conclusions: BCRP would be implicated in the resistance to chemotherapies in AML. But these are the patients expressing both BCRP and Pgp who have the poorest prognosis.
引用
收藏
页码:7896 / 7902
页数:7
相关论文
共 40 条
[1]   Low levels of ABCG2 expression in adult AML blast samples [J].
Abbott, BL ;
Colapietro, AM ;
Barnes, Y ;
Marini, F ;
Andreeff, M ;
Sorrentino, BP .
BLOOD, 2002, 100 (13) :4594-4601
[2]  
Allikmets R, 1998, CANCER RES, V58, P5337
[3]  
[Anonymous], 1998, Br J Haematol, V103, P100
[4]   Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia [J].
Archimbaud, E ;
Jehn, U ;
Thomas, X ;
De Cataldo, F ;
Fillet, G ;
Belhabri, A ;
Peaud, PY ;
Martin, C ;
Amadori, S ;
Willemze, R .
LEUKEMIA, 1999, 13 (06) :843-849
[5]   Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 [J].
Baer, MR ;
George, SL ;
Dodge, RK ;
O'Loughlin, KL ;
Minderman, H ;
Caligiuri, MA ;
Anastasi, J ;
Powell, BL ;
Kolitz, JE ;
Schiffer, CA ;
Bloomfield, CD ;
Larson, RA .
BLOOD, 2002, 100 (04) :1224-1232
[6]   Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period [J].
Baudard, M ;
Beauchamp-Nicoud, A ;
Delmer, A ;
Rio, B ;
Blanc, CM ;
Zittoun, R ;
Marie, JP .
LEUKEMIA, 1999, 13 (10) :1481-1490
[7]   THE MORPHOLOGICAL CLASSIFICATION OF ACUTE LYMPHOBLASTIC-LEUKEMIA - CONCORDANCE AMONG OBSERVERS AND CLINICAL CORRELATIONS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1981, 47 (04) :553-+
[8]   Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival [J].
Borg, AG ;
Burgess, R ;
Green, LM ;
Scheper, RJ ;
Yin, JAL .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (04) :1083-1091
[9]   P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy [J].
Broxterman, HJ ;
Sonneveld, P ;
van Putten, WJL ;
Lankelma, J ;
Eekman, CA ;
Ossenkoppele, GJ ;
Pinedo, HM ;
Löwenberg, B ;
Schuurhuis, GJ .
LEUKEMIA, 2000, 14 (06) :1018-1024
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187